Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBUMIM: Human Albumin in Septic Shock
NCT05645887Phase 2Withdrawn
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of human albumin in septic shock. Planned start Feb 2024; status: withdrawn.
02
Drugs
human albumin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05645887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645887.